

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Nagy et al.

Serial No.: 10/001,934

Art Unit: 1643

Filed: November 15, 2001

Examiner: K. Canella

Entitled: HUMAN POLYPEPTIDES CAUSING  
OR LEADING TO THE KILLING OF  
CELLS INCLUDING LYMPHOID  
TUMOR CELLS

Attorney Docket No.: GPC-259.3 US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## REVOCATION OF POWER OF ATTORNEY UNDER 37 C.F.R. §1.36; APPOINTMENT OF NEW REPRESENTATIVES

Sir:


The undersigned, as an officer empowered to execute such documents on behalf of the assignee (GPC Biotech AG) of an undivided interest in and to the above-identified patent application by virtue of an assignment recorded at Reel 012596, 014288, Frame 0742, 0937, hereby revokes all prior powers of attorney and appoints the attorneys associated with Customer Number 29425 as its attorneys, with full power of substitution and revocation to prosecute this application on its behalf and to transact all business before the Patent and Trademark Office in connection therewith.

All future correspondence relating to this application should continue to be directed to:


Leon R. Yankwich, Esq.  
Yankwich & Associates, P.C.  
201 Broadway  
Cambridge, Massachusetts 02139  
telephone: 617-374-3700  
telecopier: 617-374-0055

Respectfully submitted,

26 August 2001  
Date

  
David Bancroft  
VP Intellectual Property  
GPC Biotech AG.

  
Dr. Thomas Holtschke  
GPC Biotech AG  
Quality Assurance

**STATEMENT UNDER 37 CFR 3.73(b)**Applicant/Patent Owner: NAGY, et al.Application No./Patent No.: 10/001,934Filed/Issue Date: November 15, 2001Titled: HUMAN POLYPEPTIDES CAUSING OR LEADING TO THE KILLING OF CELLS INCLUDING LYMPHOID TUMOR CELLS

GPC Biotech AG

, a

German corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1.  the assignee of the entire right, title, and interest in;
2.  an assignee of less than the entire right, title, and interest in  
(The extent (by percentage) of its ownership interest is 60 %); or
3.  the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made) the patent application/patent identified above, by virtue of either:

A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel                   , Frame                   , or for which a copy therefore is attached.

OR

B.  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Zoltan NAGY and Christoph BRUNNER To: GPC Biotech AG

The document was recorded in the United States Patent and Trademark Office at  
Reel 012596, Frame 0742, or for which a copy thereof is attached.

2. From: Robert RAUCHENBERGER To: GPC Biotech AG

The document was recorded in the United States Patent and Trademark Office at  
Reel 014288, Frame 0937, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_


The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

Additional documents in the chain of title are listed on a supplemental sheet(s).

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

  
Signature

April 14, 2009

Date

David G. O'Brien, Registration No. 46,125

Attorney for Assignees

Printed or Typed Name

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Nagy et al.

Serial No.: 10/001,934

Art Unit 1643

Filed: November 15, 2001

Examiner: K. Canella

Entitled: HUMAN POLYPEPTIDES CAUSING  
OR LEADING TO THE KILLING OF  
CELLS INCLUDING LYMPHOID  
TUMOR CELLS

Attorney Docket No.: GPC-259.3 US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

## REVOCATION OF POWER OF ATTORNEY UNDER 37 C.F.R. §1.36; APPOINTMENT OF NEW REPRESENTATIVES

Sir:

The undersigned, as an officer empowered to execute such documents on behalf of the assignee (Morphosys AG) of an undivided interest in and to the above-identified patent application by virtue of an assignment recorded at Reel 012596, Frame 0755, hereby revokes all prior powers of attorney and appoints the attorneys associated with Customer Number 29425 as its attorneys, with full power of substitution and revocation to prosecute this application on its behalf and to transact all business before the Patent and Trademark Office in connection therewith.

All future correspondence relating to this application should continue to be directed to:

Leon R. Yankwich, Esq.  
Yankwich & Associates, P.C.  
201 Broadway  
Cambridge, Massachusetts 02139  
telephone: 617-374-3700  
telecopier: 617-374-0055

Respectfully submitted,

August 26, 2008

Date

Name: Dr. Stephan S. Uhl  
Title: Morphosys AG

i.V. P. H.  
Signature of Bernd Hutter  
Bernd Hutter  
S. Manager, Licensing & IP



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**STATEMENT UNDER 37 CFR 3.73(b)**

Applicant/Patent Owner: NAGY, et al.

Application No./Patent No.: 10/001,934

Filed/Issue Date: November 15, 2001

Titled: HUMAN POLYPEPTIDES CAUSING OR LEADING TO THE KILLING OF CELLS INCLUDING LYMPHOID TUMOR CELLS

Morphosys AG

(Name of Assignee)

, a German corporation

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1.  the assignee of the entire right, title, and interest in;
2.  an assignee of less than the entire right, title, and interest in  
(The extent (by percentage) of its ownership interest is 40 %); or
3.  the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)

the patent application/patent identified above, by virtue of either:

A.  An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy therefore is attached.

OR

B.  A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Michael Tesar and Elisabeth Thomassen-Wolf To: Morphosys AG

The document was recorded in the United States Patent and Trademark Office at  
Reel 012596, Frame 0755, or for which a copy thereof is attached.

2. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

3. From: \_\_\_\_\_ To: \_\_\_\_\_

The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

 Additional documents in the chain of title are listed on a supplemental sheet(s).

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

April 14, 2009

Date

David G. O'Brien, Registration No. 46,125

Attorney for Assignees

Printed or Typed Name

Title

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.